Tag: Pharmaceutical Industry
ATTR-CM Drug Race: Alnylam’s Entry
Alnylam's Amvuttra: A Game-Changer in the ATTR-CM Drug RaceAlnylam Pharmaceuticals has made waves in the pharmaceutical industry with the FDA's recent approval of their RNAi therapy, Amvuttra, for the treatment of transthyretin amyloid cardiomyopathy...
Trump’s Approach to Drug Pricing Plan: What to Expect
President Trump is like totally gonna try to push this “most-favored nation” policy next week to like bring down drug prices in the U.S. It’s gonna shake things up for sure, especially for the...
Expanding Access to HIV Prevention Drug: ViiV Faces Criticism
ViiV Healthcare recently announced plans to increase access to its HIV prevention medication in low- and middle-income countries. This marks the second time in two years that the company has taken such steps. Despite...
FDA Requests Further Research before Approving MDMA Therapy
The Food and Drug Administration (FDA) recently declined to approve MDMA-assisted therapy for the treatment of post-traumatic stress disorder (PTSD), citing insufficient data to support its use. The FDA requested additional clinical trials to...
Threat to Pharmaceutical Public-Private Partnerships: Gilead’s Short-Term Win
In December 2024, a group of legal, medical, and public health experts united to file an amicus brief in support of the U.S. government in a groundbreaking patent lawsuit against Gilead Sciences Inc., a...
CRISPR Crisis, RFK Jr. Promises, Non-Opioid Pain Drug Solution
In the fast-paced world of biotechnology, the landscape is constantly shifting, with new developments and challenges emerging every day. The recent turmoil in the CRISPR gene editing field has left many wondering about the...
Assessing the Cost-Effectiveness of Alzheimer’s Drug Donanemab in the U.K.
The recent decision by the U.K.'s National Institute for Health and Care Excellence (NICE) regarding the cost-effectiveness of the Alzheimer's drug Donanemab, also known as Kisunla, has raised concerns about its accessibility to patients....
Pfizer CEO’s Vision for Leading Cancer and Obesity Treatments
Albert Bourla, the CEO of Pfizer, is looking to shift the focus of the company from its successful COVID-19 vaccine and antiviral Paxlovid to new investments in drugs for cancer and obesity. While Pfizer's...
Novo Nordisk’s Strategy in Winning Over GLP-1 Patients through Telehealth
Katie Palmer, the expert in telehealth, clinical artificial intelligence, and the health data economy, is all about exploring how digital health care impacts patients, providers, and businesses. You can hit her up on Signal...
New GSK Drug Approval Poses Competition for Dupixent
Sign up for our biotech newsletter to keep up with the latest in the science and politics driving the biotech industry. Sorry for the delay in getting this newsletter to you today - technical...
Sanofi Acquires New Alzheimer’s Drug: Expansion of Pipeline
Sanofi Snags Vigil Neuroscience for Alzheimer's DrugSo, like, Sanofi, the French drug maker, just dropped $470 million to acquire Vigil Neuroscience, a small biotech company. And get this, they're adding an experimental treatment for...
Suspend U.S. patents on medicines to fight U.S. tariffs
In the wake of the recent imposition of 25% tariffs on goods from Canada by the Trump administration, the Canadian government is responding with tariffs of its own. Amidst this escalating trade conflict, there...
